Skip to main content

Table 1 Clinicopathological correlation of VISTA expression in 183 HCC patients

From: VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma

Feature Total (N) VISTA P VISTA (tumor cell) P VISTA (immune cell) P
Pos (n, %) Neg (n, %) Pos (n, %) Neg (n, %) Pos (n, %) Neg (n, %)
Age(years)
  > 50 108 36(33.3%) 72(66.7%) 0.173 20(18.5%) 68(81.5%) 0.351 22(20.4%) 86(79.6%) 0.138
  ≤ 50 75 18(24.0%) 57(76.0%)   10(13.3%) 65(86.7%)   9(12.0%) 66(88.0%)  
Gender
 Male 157 48(30.6%) 109(69.4%) 0.438 27(17.2%) 130(82.8%) 0.470 28(17.8%) 129(82.2%) 0.428
 Female 26 6(23.1%) 20(76.9%)   3(11.5%) 23(88.5%)   3(11.5%) 23(88.5%)  
Tumor size
  ≤ 5 cm 91 31(34.1%) 60(65.9%) 0.804 20(22.0%) 71(78.0%) 0.042* 19(20.9%) 72(79.1%) 0.158
  > 5 cm 92 23(25.0%) 69(75.0%)   10(10.9%) 82(89.1%)   12(13.0%) 80(87.0%)  
TNM stage
 I 73 25(34.2%) 48(65.8%) 0.294 13(17.8%) 60(82.8%) 0.272 17(23.3%) 56(76.7%) 0.261
 II 60 14(23.3%) 46(76.7%)   7(11.7%) 53(88.3%)   8(13.3%) 52(86.7%)  
 III-IV 42 15(35.7%) 27(64.3%)   10(23.8%) 32(76.2%)   6(14.3%) 36(85.7%)  
Pathological grade
 I-II 119 29(24.4%) 90(75.6%) 0.038* 16(13.4%) 103(86.6%) 0.142 18(15.1%) 101(84.9%) 0.372
 III-IV 64 25(39.1%) 39(60.9%)   14(21.9%) 50(78.1%)   13(20.3%) 51(79.7%)  
Liver cirrhosis
 Yes 69 26(22.8%) 88(77.2%) 0.011* 13(11.4%) 101(88.6%) 0.019* 17(14.9%) 97(85.1%) 0.347
 No 114 28(40.6%) 41(59.4%)   17(24.6%) 52(75.4%)   14(20.3%) 55(79.7%)  
CD8+TILs
 Yes 61 31(50.8%) 30(49.2%) 0.000* 19(31.1%) 42(68.9%) 0.000* 18(29.5%) 43(70.5%) 0.001*
 No 122 23(18.9%) 99(81.1%)   11(9.0%) 111(91.0%)   13(10.7%) 109(89.3%)  
  1. VISTA V-domain Ig suppressor of T cell activation, Pos positive, Neg negative, HCC hepatocellular carcinoma, TILs tumor-infiltrating lymphocytes
  2. *The values had statistically significant differences